Inozyme Pharma Inc. (INZY)
NASDAQ: INZY
· Real-Time Price · USD
4.00
0.00 (0.00%)
At close: Jun 30, 2025, 3:59 PM
Inozyme Pharma Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -28.04M | -27.07M | -24.57M | -27.03M | -23.35M | -21.54M | -16.64M | -15.58M | -17.4M | -18.54M | -16.37M | -15.26M | -16.88M | -18.75M | -14.28M | -12.54M | -11.05M |
Depreciation & Amortization | -509K | 177K | 195K | 188K | 182K | 306K | 208K | 209K | 207K | 198K | 189K | 179K | 178K | 182K | 167K | 167K | 158K |
Stock-Based Compensation | 1.86M | 1.97M | 2.13M | 2.16M | 1.69M | 1.67M | 1.67M | 1.6M | 2.09M | 1.89M | 1.85M | 2.19M | 1.75M | 2.02M | 1.75M | 1.81M | 1.58M |
Other Working Capital | n/a | 5.5M | -603K | 798K | -2.34M | 3.77M | -2.93M | -1.15M | -1.39M | 1.3M | 91K | -493K | 961K | 1.18M | 136K | 1.28M | -1.84M |
Other Non-Cash Items | n/a | -77K | -359K | 43K | -664K | 1.28M | 313K | 280K | -549K | -396K | -358K | -401K | 27K | 99K | 96K | 93K | 90K |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | -3.13M | -1.48M | -1.1M | n/a | n/a | n/a | n/a | n/a | 24K | 30K | 58K | 58K |
Change in Working Capital | n/a | 5.82M | -1.92M | 2.16M | -1.34M | 2.92M | -2.94M | -950K | -2.12M | 2.46M | 178K | -1.39M | 767K | 2.98M | -65K | 376K | -3.21M |
Operating Cash Flow | -29.15M | -19.19M | -24.53M | -23.66M | -24.53M | -18.49M | -18.87M | -15.55M | -17.77M | -14.4M | -14.51M | -14.69M | -14.16M | -13.44M | -12.3M | -10.03M | -12.38M |
Capital Expenditures | n/a | -17K | -13K | n/a | -32K | -105K | -7K | -11K | -175K | -46K | -147K | -200K | -17K | -40K | -79K | -190K | -88K |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | 6.37K | 44.61K | 16.32K | -13.94K | n/a | 8.11K | 22.73K | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | -17.93M | -28.55M | -27.71M | -49.46M | -49.32M | -57.87M | -104.59M | -60.82M | -46.06M | -25.99M | -44.36M | -51.23M | -30.42M | -16.97M | -42.96M | -23.49M | -38.55M |
Sales Maturities Of Investments | 51.62M | 44.01M | 51.08M | 67.28M | 59.75M | 51.5M | 59.98M | 44.5M | 60M | 29.25M | 36.25M | 28.5M | 53M | 26.5M | 56.1M | 43.35M | 39.21M |
Other Investing Acitivies | n/a | n/a | n/a | 17.82M | 10.43M | -6.37K | -44.61K | -16.32K | 13.94K | n/a | -8.11K | -22.73K | 22.58M | 9.53M | 13.14M | 19.86M | 661K |
Investing Cash Flow | 33.68M | 15.44M | 23.35M | 17.82M | 10.39M | -6.47M | -44.62M | -16.33M | 13.77M | 3.22M | -8.26M | -22.93M | 22.56M | 9.49M | 13.06M | 19.67M | 573K |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | 12.5M | n/a | 7.5M | 20M | n/a | 4.05M | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | 148K | n/a | n/a | n/a | 96K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | n/a | 177K | 83K | 458K | 159K | 16K | 153K | 16.14M | 96K | n/a | 165K | 68.33M | 240K | 11K | 237K | 112K | 249K |
Financial Cash Flow | 228K | 258K | 10.52M | 458K | 159K | 12.52M | 69.72M | 23.64M | 20.1M | n/a | 4.21M | 68.33M | 240K | 11K | 237K | 112K | 249K |
Net Cash Flow | 4.76M | -3.49M | 9.65M | -5.38M | -13.97M | -12.31M | 6.05M | -8.22M | 16.11M | -11.13M | -18.58M | 30.68M | 8.63M | -3.91M | 990K | 9.75M | -11.55M |
Free Cash Flow | -29.15M | -19.2M | -24.54M | -23.66M | -24.57M | -18.59M | -18.88M | -15.56M | -17.95M | -14.45M | -14.66M | -14.89M | -14.18M | -13.48M | -12.38M | -10.22M | -12.46M |